A-Bio Pharmaceuticals is Asia’s leading biologics contract manufacturer providing a full range of manufacturing solutions for mammalian cell culture systems.

Adamas Pharmaceuticals Inc is a global pharmaceutical company focused on the development and commercialization of superior combination therapeutics.

Addex Pharmaceuticals discovers and develops allosteric modulators for human health.

Aderis Pharmaceuticals develops a new generation of pharmaceuticals targeting CNS, cardiovascular and renal diseases.

Artisan Pharma is dedicated to bringing best-in-class critical-care and hospital-based therapeutics to patients.

Codexis proprietary technology enables cost-effective, efficient and environmentally sound production of pharmaceuticals, transportation fuels, and industrial chemicals.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company dedicated to novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Five Prime Therapeutics, Inc. is a clinical stage biotech company discovering innovative protein and antibody therapeutics.

FORMA Therapeutics integrates transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.

Idenix (NASDAQ: IDIX) develops drugs for the treatment of human viral and other infectious disease, focusing is on hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Inviragen is a leading international biotech company focussing on the development of prophylactic vaccines for global emerging infectious diseases with lead programs in dengue virus and EV71 (Hand Foot and Mouth disease).

Formerly known as Microbia, Ironwood pursues clinical candidates with the greatest potential to make a difference in patients' lives.

Kadmus is a privately-held, venture-capital backed biotechnology company created to exploit opportunities in the endocannabinoid field.

KaloBios Pharmaceuticals uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics.

Kalypsys is a biopharmaceutical company with clinical stage pharmaceutical products.

Lonza Biologics Tuas is a joint venture between Bio*One Capital and Lonza Group which established a commercial-scale biologics facility in Singapore.

Maccine is an established AAALAC-accredited GLP-compliant preclinical CRO providing services including customized translational efficacy model development for various therapeutic areas.

MerLion is an anti-infectives focused drug discovery and development company with one of the world's largest and most diverse natural product collections.

Develops new generation of cost-effective bioprocesses by harnessing microbes for the production of chemicals from renewable raw materials.

Perlegen commercializes high-value molecular genetic tests that will significantly improve the clinical decision-making process and ultimately improve patient treatment outcomes.

Acquired by Evotec AG in 2007, Renovis (NASDAQ:RNVS) develops new drugs for pain and inflammation.

Revance Therapeutics is dedicated to developing the next generation of innovative products in dermatology and aesthetic medicine.

S*BIO is an oncology-focused drug discovery and development company with a strong emerging pipeline of drug candidates including two clinical stage programmes in HDAC and JAK-2kinases.

Acquired by Daiichi Sankyo in May 2008, U3 Pharma is an emerging leader in targeted cancer drug development.

Vanda (NASDAQ: VNDX) is working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients.